Altropane

Drug Profile

Altropane

Alternative Names: 123-I Altropane®; [123I]-E-IACFT Injection; [123I]NAV5001; Altropane; CFT; Iodine-123-E-IACFT Injection; NAV-5001; O 587

Latest Information Update: 29 Sep 2016

Price : $50

At a glance

  • Originator Harvard University
  • Developer Alseres Pharmaceuticals
  • Class Contrast media; Esters; Fluorobenzenes; Iodine radioisotopes; Radiopharmaceutical diagnostics; Small molecules; Tropanes
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Parkinsonian disorders
  • Phase II Dementia
  • No development reported Attention-deficit hyperactivity disorder

Most Recent Events

  • 04 Jun 2015 NAV 2001 is still in phase III development for Parkinsonian disorders (Diagnosis) in USA
  • 04 Jun 2015 Altropane® is available for licensing as of 04 Jun 2015. http://www.alseres.com/
  • 27 Apr 2015 Alseres terminates sub-license agreement with Navidea Biopharmaceuticals for NAV 5001
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top